Hemolytic anemia due to pyruvate kinase deficiency coexistent with the alpha thalassemia trait and chronic myeloid leukemia.
作者信息
Shrestha Nirmal, Khurana Harshit, Verghese Renjith, Mishra Yogendra
机构信息
Armed Forces Medical College, Pune, India.
Armed Forces Medical College, Pune, India.
出版信息
Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S305-S308. doi: 10.1016/j.htct.2024.04.130. Epub 2024 Sep 12.
Abstract
摘要
相似文献
1
Hemolytic anemia due to pyruvate kinase deficiency coexistent with the alpha thalassemia trait and chronic myeloid leukemia.
Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S305-S308. doi: 10.1016/j.htct.2024.04.130. Epub 2024 Sep 12.
2
Dyserythropoiesis in a child with pyruvate kinase deficiency and coexistent unilateral multicystic dysplastic kidney.
Pediatr Blood Cancer. 2014 Aug;61(8):1463-5. doi: 10.1002/pbc.24953. Epub 2014 Jan 30.
3
Novel AK-1 gene variants combined with thalassemia causing rare hereditary non-spherocytic hemolytic anemia in a Chinese family.
Ann Hematol. 2025 Mar;104(3):2035-2043. doi: 10.1007/s00277-025-06289-y. Epub 2025 Feb 28.
4
Preleukemia manifested by hemolytic anemia with pyruvate-kinase deficiency.
Arch Intern Med. 1986 Apr;146(4):785-6.
5
Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency.
Curr Med Chem. 2024;31(6):683-687. doi: 10.2174/0929867330666230430002709.
6
[Inherited hemolytic anemia due to pyruvate kinase deficiency: II. Density-layer centrifugation of erythrocytes (author's transl)].
Med Klin. 1979 May 4;74(18):691-4.
7
Microcytic anemia in children: parallel screening for iron deficiency and thalassemia provides a useful opportunity for thalassemia prevention in low- and middle-income countries.
Pediatr Hematol Oncol. 2020 May;37(4):326-336. doi: 10.1080/08880018.2020.1725200. Epub 2020 Feb 19.
8
Coexistence of alpha-thalassemia and a new pyruvate kinase variant: PK Fukien.
Acta Haematol. 1983;69(1):3-8. doi: 10.1159/000206830.
9
Mitapivat for Acquired Pyruvate Kinase Deficiency.
Pediatr Blood Cancer. 2025 Feb;72(2):e31440. doi: 10.1002/pbc.31440. Epub 2024 Nov 13.
10
[ELECTROPHORETIC STUDY OF THE SOLUBLE PROTEINS OF ERYTHROCYTIC STROMA. II. ERYTHROCYTES OF HEMOPATHIC SUBJECTS].
Med Clin Sper. 1963 Nov-Dec;13:533-43.
本文引用的文献
1
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.
Lancet. 2022 Aug 13;400(10351):493-501. doi: 10.1016/S0140-6736(22)01337-X.
2
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
N Engl J Med. 2019 Sep 5;381(10):933-944. doi: 10.1056/NEJMoa1902678.
3
Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency.
Am J Hematol. 2019 Jan;94(1):149-161. doi: 10.1002/ajh.25325. Epub 2018 Nov 28.
4
Coexistence of alpha-thalassemia and a new pyruvate kinase variant: PK Fukien.
Acta Haematol. 1983;69(1):3-8. doi: 10.1159/000206830.
5
An unusual hematological syndrome with pyruvate-kinase deficiency and thalassemia minor in the kindreds.
Acta Haematol. 1968;39(6):345-58. doi: 10.1159/000208980.
6
Haemolytic anaemia with hereditary pyruvate kinase instability developing acute leukaemia.
Scand J Haematol. 1975 May;14(4):249-57. doi: 10.1111/j.1600-0609.1975.tb02424.x.
7
Chronic myelomonocytic leukemia associated with hereditary pyruvate kinase deficiency and multiple acquired erythrocyte abnormalities.
Acta Haematol. 1979;61(3):168-74. doi: 10.1159/000207651.
Zotero 插件